CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 48 enrolled
Drug / intervention
Acalabrutinib (Arm A) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02337829
NCT02337829Phase 2Completed
CompareCT.gov

A Phase II Study Using ACP-196 (Acalabrutinib) in Patients With Relapsed/Refractory and Treatment-naïve Deletion 17p CLL/SLL: Pharmacodynamic Assessment of BTK Inhibition and Antitumor Response.

Acerta Pharma BV·interventional·Posted Jan 14, 2015·Updated Jan 8, 2026

In Brief

A Phase 2 clinical trial evaluating Acalabrutinib (Arm A) and Acalabrutinib (Arm B) for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. Completed, enrolled 48 participants across 1 site.

Detailed Summary

This study is to determine the response to acalabrutinib in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH)

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 14, 2015
Enrollment StartJan 12, 2015
Primary CompletionJun 26, 2020
Study CompletionOct 31, 2025
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 11.5 years ago

Interventions

Acalabrutinib (Arm A)drug

* A1a) acalabrutinib, dose A daily: biopsy (T) schedule W; * A1b) acalabrutinib, dose A daily: biopsy (T) schedule V. * A2a) acalabrutinib, dose B q 12 hours: biopsy (T) schedule Y; * A2b) acalabrutinib, dose B q 12 hours; biopsy (T) schedule Z

Acalabrutinib (Arm B)drug

B1c) acalabrutinib, dose A daily: biopsy (U) schedule W; • B2c) acalabrutinib, dose B q12 hours: biopsy (U)) schedule Y.